リウマチ性関節炎に対する抗炎症治療と 第"回心筋梗塞後の死亡率との間には関連性がありますか?
M Skielta1, L Söderström2, S Rantapää-Dahlqvist1
1Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden.
Scandinavian journal of rheumatology
|August 29, 2025
まとめ
抗炎症薬は,急性心筋梗塞 (AMI) の生存に様々な効果を示した. コルチコステロイドは死亡リスクを増加させ,ある疾患変異薬は関節リウマチ患者の生存率を向上させた.
科学分野:
- 心臓病科
- リウマトロジ
- 薬理学について
背景:
- 急性心筋梗塞 (AMI) は,世界中で主要な死因です.
- リウマチ性関節炎 (RA) は,心血管疾患のリスクの増加に関連する炎症性疾患です.
- 抗炎症療法がRA患者におけるAMIのアウトカムに与える影響は完全に理解されていません.
研究 の 目的:
- AMI前抗炎症療法とAMI後の365日生存期間との関連性を分析する.
- リウマチ性関節炎 (RA) の患者と無患者の関連を比較する.
主な方法:
- スウェーデンのレジストリデータ (2006年−2017年) の遡及分析で,初発性AMI患者 (RA患者3725) が報告されました.
- 抗炎症薬の分類:コルチコステロイド,NSAIDs,csDMARDs,抗TNFs
- 30日間の死亡率のロジスティック回帰と31日~365日間の死亡率のコックスモデル
主要な成果:
- 抗炎症療法とAMI後の30日生存期との間に有意な関連性はない.
- コルチコステロイドの使用は,RA患者およびRA患者以外の患者において,死亡率の増加 (31- 365日) と関連していました.
- 従来の合成疾患変容性抗レウマティック薬 (csDMARDs) と抗腫瘍死滅因子 (anti- TNF) の治療は,RA患者の生存率の改善と関連していました.
- csDMARDsは,RAでない患者の死亡率の増加と関連していました.
結論:
- 抗炎症治療のタイミングとタイプは,特に30日後のAMI後の生存に大きく影響します.
- コルチコステロイドは死亡リスクをもたらしますが,csDMARDsとanti- TNFsは,AMI後のRA患者の生存に利益をもたらす可能性があります.
関連する概念動画
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:23Rheumatic Heart Disease I: Introduction
38
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
38
01:21Myocarditis I: Introduction
28
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
28
01:20Rheumatic Heart Disease IV: Nursing Management
36
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
36
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505